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The Utility of Health States After Stroke
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Background—To perform decision analyses that include stroke as one of the possible health states, the utilities of stroke
states must be determined. We reviewed the literature to obtain estimates of the utility of stroke and explored the impact
of the study population and the elicitation method.
Summary of Review—We searched various databases for articles reporting empirical assessment of utilities. Mean utilities
of major stroke (Rankin Scale 4 to 5) and minor stroke (Rankin Scale 2 to 3) were calculated, stratified by study
population and elicitation method. Additionally, the modified Rankin Scale was mapped onto the EuroQol classification
system. Utilities were obtained from 23 articles. Patients at risk for stroke assigned utilities of 0.26 and 0.55 to major
and minor stroke, respectively. Stroke survivors assigned higher utilities to both major (0.41) and minor stroke (0.72).
The EuroQol completed by stroke survivors revealed a utility of 0.32 and 0.71 for major and minor stroke, respectively.
Utilities elicited by the Standard Gamble were generally higher, while those obtained by the Visual Analogue Scale were
lower than the Time Trade Off values. Remaining variation between utilities may be caused by differences in definitions
of the health states. The mapped EuroQol indicated a utility of 0.64 for minor stroke and a value just below zero for
major stroke.
Conclusions—For minor stroke, a utility between 0.50 and 0.70 seems to be reasonable for both decision analyses and
cost-effectiveness studies. The utility of major stroke may range between 0 and 0.30 and may possibly be negative.
(Stroke. 2001;32:1425-1429.)
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Cost-effectiveness is becoming an important criterion inthe evaluation of new treatments. The health state stroke
occurs in many decision analyses and cost-effectiveness
analyses, eg, in the evaluation of treatment of stroke,1 atrial
fibrillation,2 or deep vein thrombosis.3 Quality-adjusted life-
years (QALYs) are usually the main outcome in these type of
analyses. QALYs are calculated by multiplying the time spent
in each health state by the value assigned to the particular
health state.4 To calculate QALYs, numerical judgments of
the desirability of the various outcomes must be determined.
These values are called utilities. Most health states have a
utility between 0 (death) and 1 (perfect health). Utilities of
very poor health states may even be negative. Utilities can be
assigned by experts or can be elicited from patients or healthy
people. In the present study we restricted attention to elicita-
tions. Common methods for eliciting utilities are the Time
Trade Off method (TTO), the Standard Gamble (SG), and the
Visual Analogue Scale (VAS).4 They are also used in health
state classification systems such as the Health Utility Index
(HUI)5 or the EuroQol.6 In these systems, patients in a health
state complete a descriptive quality-of-life questionnaire.
Utilities are assigned by means of a scoring table based on
preferences elicited from the general public. The latter are
measured through the SG, TTO, or VAS method.7
There have been many debates on the appropriate popula-
tion from which utilities should be elicited. It has been argued
that the healthy community is appropriate for cost-
effectiveness analyses from the societal perspective and that
patients at risk for stroke are more suited for decision
analyses from the patients’ perspective.8 Nonetheless, the
effect of the type of study population on utility scores for
stroke has not been studied extensively. Hallan et al9 elicited
utilities from 3 different study populations and reported a
utility of 0.54 for major stroke (at ages 45 to 64 years) for
healthy people but a utility of up to 0.85 for stroke survivors.
We performed a systematic review of the literature on the
utility of stroke and explored the impact of the study
population and the elicitation method on the utility estimates.
We compared these estimates with utilities obtained by the
EuroQol classification system.
Methods
We searched the literature using the electronic databases of MED-
LINE 1966–2000 (US National Library of Medicine, Bethesda, Md),
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the Web of Science 1988–2000 (Institute of Scientific Information),
and the Cochrane Library (issue 4, 2000. Oxford, UK: Update
Software), using the following search terms: stroke, cerebrovascular
accident, cerebral arterial diseases, cerebrovascular disorders, cere-
bral thrombosis, carotid artery thrombosis, Wallenberg syndrome,
cerebral hemorrhage, cerebral hematoma, apoplexy, hemiplegia, and
hemiparesis. These terms were combined with the following terms:
utility, quality of life, decision analysis, cost-benefit analysis, cost-
effectiveness analysis, and cost-utility analysis.
We examined the reference lists of all included articles for other
relevant references. Furthermore, we contacted experts in the field to
obtain published or unpublished studies reporting assessments of
utilities for stroke.
Articles were included if utilities for stroke had been elicited. The
articles were required to include the following in the Methods
section: (1) a description of the study population and (2) a descrip-
tion of the method of utility elicitation. The first author did the first
selection of articles through the electronic databases. The exclusion
criteria were applied by 2 authors (P.N.P. and P.P.W.), who also
abstracted the information, mutually independent and blinded. Dis-
agreements were resolved through discussions. We grouped the
articles according to the study population into the following catego-
ries: healthy participants, patients at risk for stroke, or stroke
survivors.
The utilities for major as well as minor disability after stroke were
examined. These 2 states were distinguished by the modified Rankin
Scale.10 Minor stroke corresponded to Rankin Scale grade 2 to 3
(minor or moderate handicap; some or significant restrictions in
lifestyle), and major stroke corresponded to Rankin Scale grade 4 to
5 (moderately severe or severe handicap; precludes independent
existence). If stroke survivors were asked to value their own health
state, we sought to obtain information about the degree of disability
of these patients. We matched the health states used in the included
publications as much as possible with those described above.
However, we included the utility in the “unspecified stroke” category
whenever the degree of severity had not been specified. If utilities in
1 study were assessed among 2 or more groups of participants, the
group size–weighted mean of these utilities was taken.
It is incorrect to compare a utility assessed with the use of death
as the lower reference point with a utility that uses another lower
reference point. The same holds true for an upper reference point
other than perfect health. Therefore, when death was not assigned a
utility of 0 or perfect health was not assigned a utility of 1, utilities
were normalized according to the following:
U2Udeath
Uperfect health2Udeath
Mean utilities weighted for sample size were calculated for each
study population (healthy participants, patients at increased risk for
stroke, and stroke survivors) and for each elicitation method (viz,
TTO, SG, VAS, HUI, EuroQol).
Additionally, the authors scored the EuroQol according to the
health state described by the modified Rankin Scale for both major
and minor stroke.10
Results
A total of 23 articles satisfied our criteria. The main charac-
teristics of the included studies are displayed in Table 1. Most
authors used the TTO or the SG; others used the VAS, HUI,
or EuroQol. Many participants were at risk for stroke and
generally middle-aged or older, with a slight male
dominance.
Stroke survivors assigned higher values to this health state
than patients at risk for stroke or healthy participants (Table
2). Patients at risk for stroke assigned slightly lower utilities
TABLE 1. Main Characteristics of the Included Studies
Author Participants n Age, y % Male Method
Adar11 Healthy adults/stroke survivors 167/11 VAS
Bosworth20 Stroke survivors 327 Mean: 66 TTO
Dorman1 Stroke survivors 152 EuroQol
Duncan22 Stroke survivors 459 Mean: 70 47% TTO
Fryback23 Stroke survivors 13 VAS
Gage2 Patients with atrial fibrillation 57 Mean: 70 86% TTO
Gage17 Patients with atrial fibrillation 70 Mean: 70 86% TTO
Gold24 Stroke survivors 102 VAS
Gore25 Stroke after thrombolysis 99 Mean: 70 59% TTO
Grootendorst26 Stroke survivors 173 Mean: 63 64% HUI
Hallan9 Healthy/stroke 66/41 Range: 20–84 40/61% SG
Indredavik27 Stroke survivors 32 VAS
Kalish28* Stroke 6 mo after myocardial infarction 714 Mean: 60 74% TTO
Kwa29 Patients with cerebral infarction 97 Mean: 63 54% VAS
Lenert30 Healthy volunteers 60 Median: 35 27% SG
Man-Son-Hing31 Healthy participants 46 Mean: 71 65% VAS
Mathias32 Patients with ischemic stroke 33 Mean: 69 59% HUI
Mittmann33 Stroke survivors in a community 16 .12 HUI
O’Meara3 Various patients 20 .50 SG
Samsa15 Patients at risk for stroke/stroke survivors 654/415 Mean: 65 52% TTO
Shin34 Patients with arteriovenous malformation 31 Mean: 37 55% SG
Solomon12 Patients undergoing carotid ultrasound 117 Mean: 73 55% VAS
Thomson35 Patients with atrial fibrillation 57 Mean: 73 54% SG
*Methods in Glasziou et al.36
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than healthy participants. The utility of an unspecified stroke
was on average close to the utility of minor stroke. Utilities
elicited by TTO were generally lower than SG utilities. VAS
and HUI utilities were lower than TTO utilities.
Part of the variation may be explained by differences in the
health states descriptions. As is shown in Table 3, consider-
able variation could be observed in the description of the
particular health states. Therefore, the mean utilities in Table
2 should be considered with care. From Table 3, utilities for
more specific stroke states can be read. Whereas the utility of
hemiplegia is 0.28 according to Adar et al,11 it is 0.13 if
aphasia is coexistent. A severe motor deficit has the lowest
utility (20.08) according to Solomon et al,12 followed by
20.02 for a severe cognitive deficit and 0.06 for a severe
language deficit.
The EuroQol, as completed by the authors, indicated a very
low, even negative, utility of major stroke (Table 2). For
minor stroke, the EuroQol revealed a utility similar to that
elicited from healthy participants or patients at risk for stroke.
Discussion
Combining the results of 23 studies, we obtained estimates of
the utility of health states after stroke. The variation between
the reported utilities may be due to the different study
TABLE 2. Mean Estimates and Range of Utilities for Minor and Major Stroke According to Study Population and Method
Participants Method
Minor Stroke Major Stroke Unspecified Stroke
Mean Range Studies Mean Range Studies Mean Range Studies
Stroke survivors TTO 0.72 0.71–0.81 22, 25 0.41 0.37–0.71 15, 22,
25
0.78 0.76–0.79 20, 28
SG 0.89 0.81–0.95 9, 34 0.72 0.45–0.93 9, 34
VAS 0.46 0.42–0.49 11, 24 0.25 0.12–0.27 11, 24 0.55 0.48–0.68 23, 24, 27, 29
HUI† 0.57 0.54–0.68 26, 32, 33
EuroQol† 0.71 1 0.32 1
At risk for stroke TTO 0.55 0.39–0.75 2, 17 0.26 0.11–0.39 2, 15, 17
SG 0.81 0.81 34 0.45 0.45 34 0.29 0.29 3
VAS 0.49 0.33–0.64 12, 35 0.05 20.02–0.19 12, 35
Healthy participants TTO
SG 0.90 0.90 9 0.57 0.54–0.60 9, 30
VAS 0.57 0.43–0.70 11, 31 0.20 0.16–0.21 11, 31
EuroQol* 0.64 0.52–0.71 20.04 20.30–0.20
*Completed by the authors; see Methods.
†Although obtained from stroke survivors, these utilities are considered preferences from the general public.7
TABLE 3. Utilities of Various Health States After Stroke (Unspecified Stroke Not Presented)
Author Method Participants Minor Stroke Utility Major Stroke Utility
Adar11* VAS Healthy Hemiparesis nondominant side 0.50 Hemiplegia without aphasia 0.28
Adar11* VAS Healthy Hemiparesis, dominant side 0.36 Hemiplegia1aphasia 0.13
Dorman1 EuroQol Stroke Independent, but not recovered after stroke 0.71 Dependent after stroke 0.32
Duncan22 TTO Stroke Rankin 2–3 0.71 Rankin 4–5 0.44
Gage2 TTO At risk Neurological event1mild residua 0.81 Moderate to severe residua 0.39
Gage17 TTO At risk Rankin 1–2 0.76 Rankin 4–5 0.11
Gold24 VAS Stroke Hemiparesis 0.42 Hemiplegia 0.27
Gore25 VAS Stroke Substantial limitation of activity and
capability
0.81 Inability to live independently or work 0.71
Hallan9 SG Healthy Rankin 2–3 0.90 Rankin 4–5 0.54
Kwa29 VAS Stroke Mildly disabled; mean Rankin score: 2 0.59
Lenert30 SG Healthy Hemiplegia1aphasia 0.60
Samsa15 TTO At risk Hemiplegia, dependent 0.27
Shin34 SG At risk Other disabling stroke 0.81 Dense hemiparesis or severe aphasia 0.45
Solomon12* VAS At risk Moderate motor deficit 0.37 Severe motor deficit 20.08
Solomon12* VAS At risk Moderate cognitive deficit 0.30 Severe cognitive deficit 20.02
Solomon12* VAS At risk Moderate language deficit 0.33 Severe language deficit 0.06
Thomson35 SG At risk Mild stroke 0.64 Severe stroke 0.19
*Mean of these rows used for Table 2.
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populations, different elicitation methods, and variation in the
health state descriptions. A recent survey of 1000 utility
estimates also included several articles in which utilities of
stroke assigned by experts were reported.13 We deliberately
chose not to include such utilities.
Study Population
Whereas the utility of major stroke assigned by healthy
participants was fairly similar to that assigned by patients at
risk for stroke, stroke survivors generally assigned higher
utilities. It is a common finding that patients actually expe-
riencing an impaired health state evaluate it higher than other
people. This is generally explained by psychological pro-
cesses such as coping and adaptation.14 Moreover, since
severely ill patients cannot be included in studies assessing
utilities, the utility of stroke may be spuriously increased if
assigned by stroke survivors because of selection bias.
In 2 studies, stroke survivors also assigned higher utilities
to hypothetical stroke states than healthy participants9 or
subjects at risk for stroke.15 In contrast, Adar et al11 observed
fairly similar utilities for stroke survivors and healthy
participants.
There have been many debates on which group of subjects
should be used to elicit utilities for various decisions. Patients
who have experienced stroke know best what life after stroke
entails. They are, however, not the people facing the deci-
sions regarding stroke. Gold et al8 suggested that utilities to
be used in cost-effectiveness analyses from the societal
perspective are best elicited from the general public because
policy decisions concern the money of the general public.
They suggested that utilities for clinical decisions are better
inferred from patients. In the latter case, patients at risk are
most similar to patients at the moment of decision; hence, if
such similarity is deemed important, the utilities of patients at
risk for stroke may be deemed most appropriate.
Elicitation Method
In general, it has been found that SG scores are higher than
TTO scores, which in turn are higher than VAS scores.16 Our
results are in agreement with this general finding. Two
studies elicited utilities from the same study populations by 2
different methods. Hallan et al9 observed the highest utility
for SG (0.61), followed by TTO (0.51) and VAS (0.31). Gage
et al17 observed a higher utility for major stroke when elicited
by SG (0.26) than by TTO (0.11).
An explanation for these findings may be as follows. The
SG method is prone to a number of biases, such as probability
transformation, which can lead to large overestimations.18
The method is also cognitively demanding. VAS scores do
not relate to tradeoffs and decisions and hence are less valid
for decision making. TTO scores do not consider risk or
discounting but are not prone to extreme biases. For these
reasons the TTO scores are presently most frequently used in
medical decision making, and we also recommend their use.
Health State Descriptions
It is likely that variations in health state descriptions play a
role in the variation between the reported utilities because
various definitions were used to describe minor or major
stroke. Moreover, if specific negative aspects of stroke are
explicitly included in the definition, participants tend to judge
this health state as less desirable. Adar et al11 reported a lower
utility when aphasia was included in the description of major
stroke (in addition to hemiplegia). Solomon et al12 observed
a paramount aversion to a severe motor impairment. A severe
cognitive deficit also elicited a negative utility, and a severe
language deficit received a utility of just above zero.
The utility of major stroke obtained by completion of the
EuroQol was lower than that reported by studies that used
healthy participants to elicit utilities. It was also lower than
the utility obtained when the EuroQol was completed by
stroke survivors in 1 study.1 For minor stroke, the utility was
fairly similar to that elicited from healthy participants or
patients at risk for stroke. Unfortunately, some items (eg,
anxiety/depression) could not be scored unambiguously.6 We
solved this problem by entering the extreme values in the
range (including the score for “I am not anxious or depressed”
and the score for “I am extremely anxious or depressed”),
after which the utility of major stroke ranged from 20.30 to
0.20. It has been shown that EuroQol is a valid measure of
health-related quality of life after stroke and is able to
discriminate between various stroke states.19 The most likely
explanation of the discrepancy may be that anxiety, depres-
sion, and pain or discomfort were not included in the health
state descriptions of the included studies assessing utilities
directly. Only Bosworth et al20 stratified their study popula-
tion according to the presence of depression. Depressed
stroke survivors assigned a mean utility of 0.61 to their health
state compared with 0.79 for nondepressed patients. Emo-
tional disorders such as depression are frequently present in
the year after stroke.21 Therefore, inclusion of depression in
the description of a health state after major stroke should be
considered.
Conclusions
As argued before, TTO utilities may be least prone to biases,
and utilities for clinical decision analyses may be best elicited
from patients at risk.8 These observations imply that a utility
of 0.55 is reasonable for minor stroke and a utility of 0.25 is
reasonable for major stroke. For cost-effectiveness analyses
from the societal perspective, Gold et al8 argue that utilities
should be elicited from the general public, preferably a health
state classification system, such as HUI or EuroQol. Since the
EuroQol is based on the TTO, a utility between 0.60 and 0.70
seems reasonable for minor stroke, while a utility between 0
and 0.30 should be considered for major stroke. If a very
severe stroke state (including a severe motor and language
deficit) is to be included in the analysis, a utility of zero or
below zero could be considered.
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